Image
Off
BIMZELX: The first and only licensed selective IL-17A and IL-17F inhibitor for moderate-to-severe plaque psoriasis1-3
BIMZELX is indicated for the treatment of moderate-to-severe plaque psoriasis in adults who are candidates for systemic therapy.1
NICE recommendation applies to severe disease (PASI ≥ 10 and DLQI > 10) and when the disease has not responded to other systemic treatments, including cyclosporin, methotrexate and phototherapy, or these options are contraindicated or not tolerated.2
Off
EXPLORE THE STORIES
Image
Off
Image
Image
Image
Image
Rapidity & durability
Image
Image
DOSING
Image
Image
Safety profile
Off
References
References
- BIMZELX Summary of Product Characteristics.
- National Institute for Health and Care Excellence. 2021. Final Appraisal Document. Bimekizumab for treating moderate to severe plaque psoriasis. https://www.nice.org.uk/guidance/ta723/documents/html-content-2
- Reich K, Papp KA, Blauvelt A, et al. Bimekizumab versus ustekinumab for the treatment of moderate to severe plaque psoriasis (BE VIVID): efficacy and safety from a 52-week, multicentre, double-blind, active comparator and placebo controlled phase 3 trial. Lancet. 2021;397(10273)487-498.
On
CHALLENGE EXPECTATIONS
Report adverse events
This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions.
Reporting forms and information can be found at www.yellowcard.mhra.gov.uk or search for MHRA Yellow Card in the Google Play or Apple App Store, or for Ireland www.hpra.ie/homepage/about-us/report-an-issue.
Adverse events should also be reported to UCB Pharma Ltd. Email UCBCares.UK@ucb.com and UCBCares.IE@ucb.com
Feature requests
Help us to grow our resource the way you want it to grow.
Date of preparation: May 2022
IE-P-BK-PSO-2200006